A large study of over 2,000 women found those who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains upon autopsy.
J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.
A large UK trial published in the New England Journal of Medicine found that women's hormone replacement therapy patches can treat prostate cancer just as effectively as standard hormone injections but with fewer severe side effects.
